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Abstract: In recent years, the monoclonal epidermal growth factor receptor (EGFR)-targeting 
antibody cetuximab was introduced into systemic therapy of colorectal cancer and gained 
an established role in the treatment of this disease. Cetuximab was shown to be active as a 
single agent in chemorefractory metastatic disease as well as in combination with varying 
chemotherapies. Recently, randomized trials demonstrated the activity of cetuximab combina-
tions in the first-line setting of metastatic colorectal cancer. Interestingly, the activity of cetux-
imab was restricted to patients with KRAS wildtype tumors, as was seen with panitumumab, 
another EGFR antibody. While 60%–70% of tumors harbor KRAS wildtype genes, 30%–40% 
of tumors express oncogenic KRAS with mutations in codons 12 and 13 causing constitutive 
activation of signaling cascades downstream of EGFR and resistance to EGFR blockade. Since 
proof of KRAS wildtype status became a prerequisite for cetuximab treatment, KRAS testing is 
being established throughout the world. Future trials will address the question which part of the 
KRAS wildtype cohort will benefit from EGFR inhibition and how to identify those patients. 
Additionally, new strategies for treatment of KRAS mutated tumors are strongly needed. Recent 
developments and future strategies will be summarized.
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Initial clinical development  
in refractory colorectal cancer
Colorectal cancer is one of the leading tumor types worldwide with about 25% of 
patients having metastatic disease at diagnosis.1 Additionally, patients with stage II 
or III disease are at considerable risk to develop recurrence and metastases after cura-
tive resection. The median survival time of patients with stage IV disease receiving 
best supportive care only is limited to around 3–6 months. Treatment with 5FU in 
combination with folinic acid in metastatic disease prolonged survival up to 12 months.2 
The introduction of irinotecan and oxaliplatin has significantly improved median sur-
vival times of colorectal cancer patients to around 20–24 months when all treatment 
options are given sequentially.3,4
In the last decade new targets have been identified for the treatment of colon cancer 
and specific drugs have been introduced into patient care. Especially the receptor for 
epidermal growth factor (EGFR) gained much interest. EGFR is expressed on more 
than 80% of colorectal cancer cells and preclinical data demonstrated its central role in 
tumor-specific functions such as proliferation, invasion, metastasis, and angiogenesis.5–8 
Cetuximab was initially developed by ImClone Systems (New York, NY, USA) as 
a specific monoclonal antibody to bind and block EGFR signaling. Cetuximab is an Cancer Management and Research 2009:1 80
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immunoglobulin G1 (IgG1)-specific human mouse chimeric 
antibody that demonstrated activity in preclinical models of 
colorectal cancer.7–9
A phase II trail of cetuximab monotherapy in 57 patients 
with chemorefractory colorectal cancer demonstrated 
modest activity with 9% response rate and a median survival 
of 6.4 months.10 The so-called BOND trial investigated 
cetuximab either as monotherapy or in combination with 
irinotecan in patients refractory to irinotecan. Cetuximab 
monotherapy was associated with a response rate of 10.8% 
and a median survival of 6.9 months in these heavily 
pretreated patients. The combination of cetuximab with 
irinotecan improved the response rate to 22.9% and 
median survival was estimated with 8.6 months.11 Based 
on these data cetuximab was approved for the treatment 
of irinotecan-refractory colon cancer by the US Food and 
Drug Administration (FDA) in February 2004 and by the 
European Medicines Agency (EMEA) in June 2004. Data of 
the cetuximab–irinotecan combination in refractory patients 
were confirmed in a single center phase II trial verifying a 
response rate of 25% and a median survival of 9.8 months.12 
Similar results were reported in a multicenter phase II trial 
from Japan confirming almost identical efficacy data in an 
Asian population.13
Further development 
as second- and third-line therapy
A large multinational trial was designed to confirm the 
results of the BOND trial in a heavily pretreated population 
with patients progressing on irinotecan-containing regimens. 
1147 patients with EGFR-positive colorectal cancer received 
cetuximab in combination with various irinotecan schedules, 
either weekly, every two weeks, or every three weeks. 
Response rates ranged between 17.3% and 21.4% depending 
on the irinotecan schedule. A mean overall survival (OS) 
time of 9.2 months was reached.14 This so-called MABEL 
trial confirmed the activity of cetuximab added to irinotecan 
in irinotecan-pretreated patients in a large population in the 
community setting. Infusion-related reactions of grades 3 and 
4 were observed in less than 1% of patients. Severity of acne-
like rash was associated with improved efficacy parameters 
such as progression-free survival (PFS).
Beside the original schedule of weekly cetuximab several 
trials attempted to investigate whether a more convenient 
schedule with infusions every other week might influence 
pharmacokinetics and efficacy of cetuximab. Similar efficacy 
results and toxicity data were observed in a schedule of cetux-
imab in a dose of 500 mg/m2 and irinotecan (180 mg/m2) 
given every two weeks as compared to previous data with 
weekly cetuximab.15,16 However, the two-weekly applications 
have not been approved yet.
Further attempts to improve the efficacy of chemotherapy 
in combination with cetuximab were performed in the 
second-line setting. Souglakos and colleagues tested the 
combination of cetuximab with oxaliplatin and capecitabine 
in patients refractory to first-line oxaliplatin-containing 
regimen in a phase II trail. The combination of cetuximab 
with capecitabine and oxaliplatin was safe. The over-
all response rate in this population was 18.7%. Time to 
tumor progression however, was short at three months.17 
In the EPIC trial, patients with oxaliplatin-refractory 
EGFR-expressing disease were treated with irinotecan 
either alone or in combination with cetuximab. In this 
large phase III trail the addition of cetuximab to irinotecan 
improved the response rate from 4.2% to 16.4% and PFS 
from 2.6 to 4.0 months. The median OS was not different 
in both groups with 10.0 and 10.7 months. The authors 
noted that 87% of patients in the irinotecan arm received 
cetuximab-containing treatments after disease progression.18 
This post-study crossover might have washed out survival 
benefits in the combination group.
Clinical trials in the first-line 
treatment of metastatic  
colorectal cancer
Initial data from first-line treatment with cetuximab were 
reported from a small cohort of 21 patients with EGFR-positive 
metastatic colon cancer receiving cetuximab in combination 
with weekly irinotecan and 5FU/FA with two dose groups 
of 5FU (1500 and 2000 mg/m2, respectively). The higher 
5FU dose was associated with diarrhoea and the dose of 
1500 mg/m2 was recommended for further trials. In this small 
patient group the overall response rate (ORR) was 67% and 
PFS reached 9.9 months.19 Early data from combinations with 
oxaliplatin were reported from a phase II trial with 43 patients 
using FOLFOX-4 as chemotherapy backbone. The confirmed 
ORR was 72%, median PFS was 10.8, and median OS was 
high with 30 months. Secondary resectability rate was 23% 
with resection of liver metastases in curative intention in 
10 patients.20 A small randomized phase II trial investigated 
the addition of cetuximab to oxaliplatin plus capecitabine 
in the first-line setting. While an improvement regarding 
response rate (41%) and PFS (7.2 months) was observed in 
the cetuximab arm, the low response rate of 14% and a PFS 
of 5.8 months in the control group were of some concern 
in this trial.21Cancer Management and Research 2009:1 81
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Data from a larger population were reported within the 
OPUS study, a large randomized phase II trial studying 
FOLFOX-4 with or without cetuximab in 338 untreated 
patients with positive EGFR staining. Response rate was 
improved from 36% to 46% in the cetuximab group. The 
difference in response rate was not significant (p = 0.064) 
for the whole patient population and PFS was identical with 
7.2 months in both arms. With increasing data on KRAS 
mutations in colorectal cancer being associated with lack of 
response in EGFR-inhibiting therapies, KRAS mutation status 
was evaluated in 233 patients. In patients with KRAS wild-
type tumors the difference in response was highly significant 
with 37% vs 61% (p = 0.011) and a lower risk of disease 
progression was observed. Patients with KRAS mutant 
tumors did not benefit from the addition of cetuximab.22
The CRYSTAL study investigated the combination of 
cetuximab with FOLFIRI in 1217 untreated patients with 
colorectal cancer in a randomized fashion. Similar to the 
OPUS trial the addition of cetuximab to chemotherapy resulted 
in an 8% increase of the ORR (p = 0.004) and PFS was 
prolonged from 8.0 to 8.9 months (p = 0.0479). Interestingly, 
PFS curves separated late with one-year PFS rates of 23% 
and 34%, respectively. When tumor tissue was analyzed for 
KRAS, mutations were detected in 36% of patients. In those 
the addition of cetuximab did not improve response or PFS. 
In wildtype patients, PFS was prolonged from 8.7 to 9.9 months 
(p = 0.017).23 See Table 1 for an overview of clinical trials.
Based on these data cetuximab has been approved for 
first-line therapy in metastatic colorectal cancer for patients 
harboring KRAS wildtype tumors. More details on the role 
of KRAS will be discussed later.
Cetuximab monotherapy 
in refractory disease
Based on a phase II-study and the mono-arm of the BOND 
trial cetuximab was introduced as monotherapy option in 
Table 1 Selected cetuximab trials. Landmark trials in the development of cetuximab according to clinical treatment lines with main 
characteristics and results such as progression-free survival (PFS) and response rate (RR). in several trials time to progression (TTP) 
was used as clinical endpoint (in parentheses). Recent studies analyzed efficacy results for KRAS wildtype patients separately. Data of 
wildtype cohorts are noted (italic) below results of the entire populations
Author Phase Patients 
(n)
Treatment line Therapy PFS (mo) RR (%)
Saltz et al 2004 ii 57 2nd (irinotecan refr.) Cet mono 1.4 9
Cunningham 
et al 2004
iii 329 2nd (irinotecan refr.) Cet + irinotecan vs 
Cet mono
4.1 vs 1.5 22.9 vs 10.8
Lenz et al 2006 ii 346 2nd (iri + oxali refr.) Cet mono 1.4 11.6
wilke et al 2008 iii 1147 2nd (irinotecan refr.) Cet + irinotecan 
(three schedules)
3.2 20.1
Souglakos et al 
2007
ii 40 2nd (previous oxaliplatin) Cet + CapOx 2.9 (TTP) 20
Sobrero et al 
2008
iii 1298 2nd (previous oxaliplatin) Cet + irinotecan vs 
irinotecan
4.0 vs 2.6 16.4 vs 4.2
Folprecht et al 
2006
ii 21 First line Cet + irinotecan/
5FU/FA
9.9 (TTP) 67
Tabernero et al 
2007
ii 43 First line Cet + FOLFOX 12.3 72
Borner et al 
2008
ii 74 First line XeLOX ± Cet 7.2 vs 5.8 (TTP) 41 vs 14
Bokemeyer et al 
2009
ii 337 First line FOLFOX-4 ± Cet 7.2 vs 7.2 (7.9 vs 7.2) 46 vs 36 (61 vs 37)
van Cutsem 
et al 2009
iii 1198 First line FOLFiRi ± Cet 8.9 vs 8.0 (9.9 vs 8.7) 46 vs 38 (59 vs 43)
Saltz et al 2007 ii 83 2nd (previous irinotecan) Cet + beva ± irinotecan 7.3 vs 4.9 (TTP) 37 vs 20
Tol et al 2009 iii 755 First line CapOx/beva ± Cet 9.6 vs 10.7 
(10.5 vs 10.6)
52.7 vs 50 
(61.4 vs 50)
Jonker et al 
2007
iii 572 2nd Cet vs BSC HR 0.68 (3.7 vs 1.9) 8 vs 0 (13 vs 0)Cancer Management and Research 2009:1 82
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irinotecan-refractory colorectal cancer.10,11 In both trials, a 
mean response of 10% was observed. Another phase II trial 
by Lenz and colleagues demonstrated a similar response 
rate of 11.6% and a median OS of 6.6 months in a cohort of 
346 patients in chemorefractory patients.24 Adverse events 
included hypersensitivity reactions, acne-like rash, asthenia, 
diarrhea, and others. Skin toxicities started within 1–3 weeks 
after initiation of cetuximab treatment. In a phase III setting 
in heavily pretreated patients, cetuximab was superior to best 
supportive care in KRAS wildtype patients with a median 
PFS of 14.8 weeks (mutant 7.2) and meaningful difference 
in OS of 9.5 months vs 4.5 months in KRAS mutants.25
Pessino and colleagues addressed the question whether 
cetuximab could be used as monotherapy in the first-line 
setting. Interestingly, the response rate of 10% in cetuximab 
monotherapy in chemonaïve patients was similar to that 
observed in pretreated patients.26 Time to progression was 
only two months. Therefore, cetuximab monotherapy can not 
be considered as effective first-line treatment.
Findings of anti-EGFR monotherapy have been reviewed 
recently.27
Combination of cetuximab 
with bevacizumab
A similar design to the BOND trial, but with the addition of 
bevacizumab, was tested in irinotecan-refractory patients in 
a small phase II study. The combination of bevacizumab plus 
cetuximab resulted in a response rate of 20% and an OS of 
11.4 months in this heavily pretreated cohort. The combina-
tion of both antibodies plus irinotecan further improved the 
response with an ORR of 37% and OS of 14.5 months.28 
The results of this BOND-2 study formed the basis for the 
randomized CAIRO2 trial investigating the addition of 
cetuximab to a combination of capecitabine, oxaliplatin, 
and bevacizumab. Although no unexpected toxicities were 
observed,29 efficacy data were surprisingly inferior for the 
cetuximab-treated patients. In the intention-to-treat (ITT) 
population PFS was 10.7 months in the control group and 
9.4 months in the cetuximab arm. In the subanalysis of the 
KRAS wildtype population there was no difference in PFS 
and OS between treatment arms. In KRAS mutant patients 
PFS was significantly lower in the cetuximab arm with 
8.6 months. Interestingly, the control group had a higher PFS 
(12.5 months) compared to all other groups.30
A similar attempt using the EGFR antibody panitumumab 
was studied in the PACCE trial. In this randomized first-
line trial panitumumab was added to either oxaliplatin- 
or irinotecan-based chemotherapy plus bevacizumab. 
The combination was associated with inferior outcome as 
compared to the control arm with PFS times of 10 vs 11.4 
months and OS of 19.4 vs 24.5 months for panitumumab 
and the control arm, respectively. Additionally, toxicities 
were significantly increased in the panitumumab arm. KRAS 
analyses resulted in inconsistent data between groups. 
Oxaliplatin-based chemotherapy plus both antibodies was 
associated with inferior response compared to the control 
group in KRAS wildtype patients.31
Based on these two negative randomized trials, the 
idea of EGFR and vascular endothelial growth factor 
(VEGF) double-targeting with monoclonal antibodies has 
failed. The underlying mechanism is not understood so far. 
One explanation could be the downregulation of VEGF 
production under EGFR inhibition. This may cause activation 
of alternative proangiogenic factors and lack of efficiency 
of VEGF blockade.
The biology of KRAS 
in EGFR-targeted treatment 
of colorectal cancer
Since the discovery of the epidermal growth factor (EGF) 
receptor in the early 1980’s,32 growing knowledge about 
ligands, activation, and signaling helped to understand its 
biological function.33 Upon activation, the transmembrane 
EGF receptor forms a dimer leading to receptor autophos-
phorylation through its tyrosine kinase activity.34 EGFR 
activates at least five different signaling pathways: the 
RAS/RAF/MAPK, the phospholipase C, the PI3K/AKT, 
the STAT, and the SRC pathways.35 Of those, RAS/RAF/
MAPK and PI3K/PTEN/AKT pathways are considered as 
central effectors of EGFR activation. Each of these finally 
triggers intracellular signals that may support the malignant 
phenotype. In recent years, increasing evidence suggested 
that self-activating or loss of function mutations could occur 
in nearly all signaling pathways and steps.
Besides alterations of p53, FAP, and other oncogenes 
activating mutations of KRAS have been described as 
part of the oncogenic transformation during development 
of colorectal cancer.36 Indeed, KRAS mutations have a 
prevalence of 30%–40% in larger series of colorectal cancer 
trials.22,23,37 While the prognostic role of mutated KRAS 
in colorectal cancer remains controversial,38,39 initial data 
from small cohorts had suggested, that in patients treated 
with cetuximab response was only observed in wildtype 
tumors.40 This finding was confirmed by in vitro experiments 
showing lack of response to cetuximab in colon cancer cells Cancer Management and Research 2009:1 83
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expressing mutant KRAS as compared to wildtype cells.41 
In a larger series of 89 patients among which 27% had KRAS 
mutant tumors, wildtype patients had a response rate of 40% 
while none of the patients with mutant tumors responded to 
cetuximab treatment.42 These findings were confirmed by 
another group analyzing 113 patients treated with cetuximab. 
Early tumor shrinkage was identified as additional predictive 
marker.43
In a randomized phase III trial comparing EGFR 
inhibition with panitumumab monotherapy to best supportive 
care in patients refractory to chemotherapy, the objective 
response for all patients treated with panitumumab was 
10%.44 In wildtype patients treated with panitumumab, the 
response rate was 17% compared to 0% in the mutant group.45 
Based on these data, panitumumab was approved as single 
agent only for patients with KRAS wildtype tumors.
Almost identical data have been reported from a random-
ized phase III trail with cetuximab monotherapy versus best 
supportive care in chemorefractory patients. In this trial 
enrolling 572 patients, the response rate was 8% vs 0% in the 
cetuximab vs control groups, respectively.46 Post-hoc KRAS 
analyses of 69% of tumors detected KRAS mutant status in 
42% of patients. In those, there was no difference in PFS 
and OS when treatment and control groups were compared. 
In wildtype patients, median OS significantly improved from 
4.8 to 9.5 months when cetuximab therapy was given.25
The KRAS analyses from the CRYSTAL and OPUS 
trials confirmed the importance of KRAS mutation status for 
EGFR-targeted therapy in the first-line treatment of meta-
static colorectal cancer. First-line cetuximab in combination 
with FOLFOX-4 significantly improved the response rate 
from 37% to 61% in KRAS wildtype tumors when cetuximab 
was added to chemotherapy. PFS was significantly improved 
from 7.2 to 7.7 months.22 A similar effect was observed in 
the CRYSTAL study using FOLFIRI as backbone with 
an increase in RR from 43% to 59% in wildtype patients 
and improvement of PFS from 8.7 to 9.9 months.23 In the 
smaller OPUS trial KRAS mutant patients seemed to do 
worse under cetuximab treatment with lower response rates 
(49% vs 33%) and PFS (8.6 vs 5.8 months) when compared 
to chemotherapy only. In the CRYSTAL trial there was no 
significantly inferior outcome in the mutant group. Whether 
this finding represents a true effect of inferior outcome caused 
by EGFR inhibition in KRAS mutant tumors in particular in 
combination with FOLFOX remains unclear.
Based on the presented data, the EMEA approved cetux-
imab treatment exclusively for patients with KRAS wildtype 
metastatic colorectal cancer.47 The American Society of 
Clinical Oncology published a provisional clinical opinion 
stating that all patients who are candidates for anti-EGFR 
therapy should have their tumors tested for KRAS mutation 
status. Patients with KRAS mutations should not receive anti-
EGFR antibodies.48 This development reflected an exciting 
step towards personalized therapy in solid tumors.
Appropriate and standardized KRAS mutation detection 
tests are subjects of practical considerations.49 Another 
important question is whether primary and metastases have 
identical KRAS mutation status. Santini and colleagues 
analyzed 38 patients with KRAS mutant tumors and found 
a high concordance of 96%. Only one patient had a wildtype 
primary and mutant metastases and three patients had mutant 
primary tumors and wildtype KRAS in their metastases.50 
Based on this data there is no need to analyze both primary 
and metastases.
Biomarkers in cetuximab therapy
In early trials, proof of positive EGFR staining on the 
tumor tissue was mandatory in order to treat only patients 
expressing the appropriate target for cetuximab. Further data 
suggested, that patients with absence of immunhistological 
EGFR staining might also respond to cetuximab treatment.51,52 
A larger translational study analyzing 346 patients found no 
correlation of EGFR-staining score and treatment response.24 
Although evidence from randomized trials is not available, 
EGFR immunohistochemical (IHC) staining is no longer 
required for cetuximab treatment according to current expert 
opinion.53 The lack of EGFR IHC to predict response may be 
related to the short presentation of receptors on the surface 
due to receptor turnover.
Further attempts to evaluate meaningful predictive 
markers for EGFR-blocking agents in colorectal cancer 
focused primarily on gene amplifications and polymorphisms 
of the EGFR gene. Increased gene copy numbers of EGFR 
as detected by fluorescent in situ hybridization (FISH) have 
been linked to an increased response rate and prolonged OS 
in cetuximab-treated patients.54 Similar results have reported 
from a panitumumab cohort.55 In patients with rectal cancer 
receiving neoadjuvant radiochemotherapy plus cetuximab, 
elevated EGFR gene copy numbers were significantly 
associated with tumor regression.56 In contrary, data suggest-
ing no evident association with EGFR gene copy number or 
mutations have been reported earlier.24 Due to the heterogene-
ity of data and problems in methodological standardization 
FISH analysis has not entered clinical routine, so far.
Several polymorphisms in the EGFR gene have been 
identified. Of those, EGFR intron-1 S/S, EGFR 497 G  A Cancer Management and Research 2009:1 84
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and EGFR R521K seem to play considerable roles.57–59 In a 
cohort of 110 patients, increased skin toxicities and treatment 
response was associated with EGFR intron-1 S/S carriers.57
Pharmacogenetic analyzes of peripheral blood allows to 
examine germ-line variants of relevant genes such as EGFR 
ligands. Variants in the ligand EGF, namely EGF 61A  G 
seemed to be associated with an improved OS compared 
to the A/A genotype.57 In another trial, analyses of EGF 
polymorphisms in KRAS wildtype tumors suggested that 
EGF 61A  G was significantly associated with decreased 
response rate and OS.60 These contradictory findings need 
to be re-evaluated in larger cohorts and should be linked to 
levels of EGF in the serum of patients.
Further potential predictive markers have been identified. 
Increased expression of EGFR ligands epiregulin and amphi-
regulin was linked to better disease control rates and longer 
PFS according to gene array studies analyzing tissue from 
110 patients.61 Indeed, treatment with cetuximab induces 
up-regulation of epiregulin, amphiregulin as well as trans-
forming growth factor-α (TGF-α), another EGFR ligand, in 
preclinical models and patients treated with cetuximab.62
Skin toxicity was reported to correlate with efficacy of 
cetuximab.14 While in patients without skin rash no objective 
response occurred, patients with increasing rash grades had 
responses ranging from 7.2% in mild rash up to 20% in severe 
skin toxicity.24 The EVEREST trial reported data from dose-
escalation of cetuximab in patients lacking skin toxicities. 
Patients receiving escalating doses up to 500 mg/m2 experi-
enced responses in 30% (13% in controls) and a median PFS 
of 4.8 months as compared to 3.9 months in controls.63 The 
lack of response in KRAS mutated tumors demonstrate that 
skin toxicity and KRAS status are independent predictive 
markers of cetuximab.64
Additional targets in the EGFR 
signaling cascade
The role of KRAS mutations has been discovered recently 
and was discussed before. Aside from KRAS further genes of 
signaling proteins might be affected by oncogenic mutation 
and associated with resistance to EGFR inhibition.
Principal effector downstream of KRAS is the serine–
threonine–kinase BRAF. A mutation of BRAF with replace-
ment of valine in codon 600 by glutamic acid resulting in 
an enhanced kinase activity independent from upstream 
signaling has been described.65 This V600E allele mutation 
occurs in approximately 10% of colorectal cancer patients. 
It is associated with microsatellite instability and poor 
survival of colon cancer patients.66,67 BRAF mutations in 
colorectal cancer cause resistance to EGFR-targeted therapy 
with shorter PFS and OS compared to nonmutated patients.68 
Remarkably, treatment with the BRAF-inhibitor sorafenib 
in in vitro experiments restored sensitivity to cetuximab in 
colon cancer cells.68
PI3K-activating mutations occur in around 13% of 
colorectal cancer patients.69 The hot spots are located in 
exon 9 and 20; they correlate with resistance to cetuximab 
in metastatic colorectal cancer in vivo and in vitro.70,71 On the 
other hand, Prenen and colleagues reported a series of 
200 patients with 12% PI3K mutants without any correlation 
of PI3K mutations to cetuximab response.72 Therefore, 
further data on this topic are urgently needed.
The PTEN tumor suppressor is a negative regulator of 
PI3K signaling. Inactivating mutations or promoter meth-
ylation cause loss of expression in 20% of microsatellite-
instable tumors and was reported to occur in up to 10% of 
colorectal cancer patients.73 Since loss of PTEN function 
results in uncontrolled PI3K activation, patients do not benefit 
from EGFR blockade with cetuximab.74–76 Interestingly, the 
concordance between primary tumor and metastases is low 
with 60%. Only PTEN loss on metastases predicted resistance 
to cetuximab plus chemotherapy in this patient cohort.76 
In in vitro experiments the effect of a PTEN-activating drug 
was shown, but it remains unclear if it would be able to induce 
re-expression of the protein.77
AKT is a serine–threonine–kinase known as a main 
effector of PI3K signaling. The E17K mutation induces an 
upstream-signal independent constitutive activation of AKT 
and resistance to cetuximab.35 This signaling pathway can 
be selectively targeted by mTOR inhibitors.78 This approach 
has already been successfully investigated in metastatic 
melanoma with constitutively activated PI3K.79
No mutations have been described in the STAT 
pathway, nor was STAT associated with resistance to EGFR 
targeting,35 although, only a small number of samples have 
been screened.
In the SRC/FAK pathway, activation may be caused 
by upregulation.35 Src mutations have not been confirmed 
in colorectal cancer.80 In vitro, SRC upregulation has been 
associated with cetuximab resistance in non-small cell 
lung cancer cell line.81 Remarkably, treatment with the 
SRC-inhibitor dasatinib restored cetuximab sensitivity.81 
In addition SRC-inhibitors were found to be effective in 
colorectal cancer in vitro.82
Another interesting target is the IGF1 receptor that can 
dimerize with EGFR and could directly interact with EGFR 
downstream signaling and bypass cetuximab blockade.83Cancer Management and Research 2009:1 85
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Resistance to EGFR-blocking therapeutics could evolve 
through alternate mechanisms causing independence of 
EGFR activation. Beside alterations in the EGFR signal 
transduction pathway tumors may escape EGFR blockade 
by increased angiogenesis, activation of alternative tyrosine 
kinases or receptor mutations (Figure 1).84,85
Future directions: immunological 
biomarkers
Antibody-dependent cell-mediated cytotoxicity (ADCC) 
is one of the main modes of therapeutic antibodies such as 
trastuzumab or rituximab.86,87 Polymorphisms in the IgG 
fragment C receptor affecting ADCC have been shown to be 
associated with efficacy of those antibodies.86,87 Zhang and 
colleagues reported two FCGR polymorphisms associated 
with efficacy of cetuximab monotherapy in 39 patients.88 This 
could be confirmed in another cohort of 69 patients treated 
with cetuximab plus irinotecan with longer PFS for patients 
with FCGRIIa-131 H/H and/or FCGRIIIa-158V/V geno-
types. The predictive effect of Fc polymorphisms remained 
independent of the KRAS status.89
Recently, expression of human leukocyte antigen-E 
(HLA-E) antigen was studied on colorectal cancer tissue. 
This nonclassical major histocompatibility complex (MHC) 
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Figure 1 Simplified EGFR-signaling pathway. Ligands are EGF,   TGF-β, eR, and AR. The two main pathways are the Pi3K/AKT/mTOR and RAS/RAF/MAPK cascades. The iGF1 
receptor can dimerize with eGFR and activate eGFR signaling.    Alternatively, downstream crosstalk between signaling cascades may occur.    Alterations of downstream effectors 
known to interfere with eGFR signaling are marked in red.
Abbreviations: AR, amphiregulin; eGF, epidermal growth factor; eGFR, epidermal growth factor receptor; eR, epiregulin; iGF1, insulin-like growth factor-1; TGF-β, transforming 
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molecule is overexpressed in human colon cancer and 
associated with inhibition of natural killer (NK)-mediated 
cell lyses and might explain the escape to immunological 
control in this cancer type. Upregulation of HLA-E was 
also associated with shorter survival of Dukes’ C patients.90 
In vitro, cetuximab-mediated cytotoxicity was hampered in 
HLA-E overexpressing cells.91 While direct antiproliferative 
effects were seen in cell lines only at high concentrations, 
ADCC was observed already in low cetuximab concentra-
tions in HLA-E normal-expressors suggesting ADCC as the 
main effect of cetuximab. The role of HLA-E overexpression 
needs to be further explored. Probably, it might serve as a 
new biomarker and future target.
Summary
EGFR-targeted therapy with cetuximab in colorectal cancer 
has made significant progress in the recent years. However, 
the detection of KRAS mutations and their potential impact 
for treatment guidance opened several new questions. 
For the future we need to identify patients who will benefit 
most from EGFR inhibition. This may be available by estab-
lishment of a reliable panel of biomarkers that can predict 
the response to cetuximab. Besides KRAS, this approach 
involves genetic analyses of ligands and downstream 
effectors. Additionally, polymorphisms of Fc receptors 
and HLA-E expression in tumor tissue should be analyzed 
and correlated to clinical outcome. Based on these evolving 
data new targets may be identified and could lead to new 
combinations of targeted drugs. Translational research in 
medical oncology remains a major challenge in the next 
years in order to provide the background for personalized 
treatment of cancer patients.
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